37 results about "Flt3 ligand" patented technology

Provided herein is a chimeric protein, which chimeric protein comprises a Flt3 ligand, or a biologically active fragment thereof, and a proteinaceous or peptidyl tumoricidal agent, or a targeting agent which binds to a receptor expressed on a tumor, and uses thereof, particularly in the treatment of malignancy. Other embodiments and uses are disclosed.

The invention provides a method for treating an autoimmune disease in a subject by administering an interferon antagonist and a Flt3 ligand (Flt3L) antagonist. The invention also provides compositions containing one or more interferon antagonists, and one or more Flt3L antagonists, an in vitro assay for determining a subject's risk for developing an autoimmune disease, and kits for use, inter alia, with the assay.

Ligands for flt3 receptors capable of transducing self-renewal signals to regulate the growth, proliferation or differentiation of progenitor cells and stem cells are disclosed. The invention is directed to anti-flt3-L antibodies and enzyme-linked immunosorbent assays comprising such antibodies.

A serum-free culture medium for hematopoietic stem cell (HSC) expansion is provided. The serum-free culture medium includes a serum-free base medium, cytokines, an umbilical cord mesenchymal stem cell conditioned medium and supplemental components. The cytokines comprise stem cell factor, thrombopoietin and hematopoietic growth factor Flt3 ligand. The umbilical cord mesenchymal stern cell conditioned medium is derived from culturing human umbilical cord mesenchymal stem cells. The supplemental components comprise vitamin C, vitamin E or a combination of vitamin C and vitamin E.

The present invention relates generally to the fields of proteins, diagnostics, therapeutics and nutrition. More particularly, the present invention provides an isolated protein molecule such as EPO, Flt3-Ligand, Flt3, PDGF-B or VEGF-165 or chimeric molecules thereof comprising at least a portion of the protein molecule, wherein the protein or chimeric molecule has a profile of measurable physiochemical parameters which is indicative of, associated with or forms the basis of, one or more pharmacological traits. The present invention further contemplates the use of the isolated protein or chimeric molecule thereof in a range of diagnostic, prophylactic, therapeutic, nutritional and / or research applications.

Flt3 ligand from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said ligand. Methods of using said reagents and diagnostic kits are also provided.

The invention provides a method for treating an autoimmune disease in a subject by administering an interferon antagonist and a Flt3 ligand (Flt3L) antagonist. The invention also provides compositions containing one or more interferon antagonists, and one or more Flt3L antagonists, an in vitro assay for determining a subject's risk for developing an autoimmune disease, and kits for use, inter alia, with the assay.

A method of generating a population of dendritic cell (DC) precursors includes obtaining a population of progenitor cells from a subject and culturing the progenitor cells in a culture medium. The culture medium can include Flt3 ligand and interleukin-6 and be free of granulocyte-macrophage colony-stimulating factor.

The invention is directed to methods of using Flt3-Ligand in hematopoietic cell transplantation procedures using nonmyeloablative conditioning regimens. This abstract is provided for the sole purpose of enabling the reader to quickly ascertain the subject matter of the technical disclosure and is not intended to be used to interpret or limit the scope or meaning of the claims.

In the present invention, CD8+ conventional dendritic cells (CD8+ cDCs) and equivalents thereof (eCD8+ cDCs) in mouse and human have been established as major source of IFN-lambda (IFN-λ) in response to double-stranded (ds) nucleic acids. The invention relates to therapeutic applications of ds nucleic acids or analogs thereof targeting CD8+ and / or eCD8+ cDCs in the prevention and / or treatment of infectious diseases, preferably viral infections, or cancer. Furthermore, the invention relates to an in vitro method for producing IFN-λ and / or generating or obtaining a population of IFN-λ producing CD8+ or eCD8+ cDCs as well as in vitro method for detecting or screening for CD8+ and / or eCD8+ cDCs. In addition, the invention relates to a Flt3-ligand or a M-CSF receptor ligand for use in increasing the level of CD8+ and / or eCD8+ cDCs in a subject suffering from an infectious disease or cancer.

Methods of treating a fibrosacroma using flt-3 ligand are disclosed, as well as methods of increasing the number of dendritic cells in a patient having a fibrosarcoma.

Disclosed are methods for partially or completely preventing or reversing the effects of asthma in a subject. The methods include administering an effective amount of a Flt3 ligand to the subject Compositions which include a Flt3 ligand and a pharmaceutically acceptable aerosolizing agent are also described, as are conjugates which include a Flt3 ligand and an allergen.

A screening method for identifying mutant polypeptides having at least one amino acid difference from a wild type protein involved in a receptor-ligand interaction is disclosed. Also disclosed are mutant polypeptides of the hematopoietic growth factor flt3-Ligand (flt3-L) identified using this method, nucleic acids encoding these flt3-L mutant polypeptides, and methods of treatment involving in vitro and in vivo use of the mutant polypeptides and nucleic acids.

The invention relates to a stem cell in-vitro multiplication method. A multiplication culture system containing niacinamide substances is adopted, a serum-free culture medium is used as a basic culture medium, and 8%-12% of fetal bovine serum, a cytokine composition and niacinamide substances are added. The cytokine composition includes a stem cell factor, thrombopoietin, an FLt3 ligand, G-CSF, IL-3 and IL-6. Compared with conventional culture systems, the culture system can effectively increase the number of hematopoietic stem cells and the cell proportion of CD34+ / Lin- and CD34+ / CD38- when culturing CD34+ cells for 1-12 weeks and is helpful to solving of the problem of insufficient cells in hematopoietic stem cell transplantation.

A method of generating a population of dendritic cell (DC) precursors includes obtaining a population of progenitor cells from a subject and culturing the progenitor cells in a culture medium. The culture medium can include Flt3 ligand and interleukin-6 and be free of granulocyte-macrophage colony-stimulating factor.

Disclosed herein are methods and compositions for treating leukemia and preventing leukemia relapse related to the administration of agents that inhibit the binding of FLT3 ligand to FLT3.

Flt3-ligand can be used to generate large numbers of dendritic cells from hematopoietic progenitor and stem cells. Flt3-ligand can be used to augment immune responses in vivo, and expand dendritic cells ex vivo. Such dendritic cells can then be used to present tumor, viral or other antigens to naive T cells, can be useful as vaccine adjuvants. When flt3-L is used and / or administered in combination with other reactive agents, e.g. CD40 binding proteins, 4-1BBL or antibodies reactive with 4-1BB, CD30 ligand antagonists, RANKL, and / or interferon alpha the combination further enhances immune responses and the effectiveness of vaccine adjuvants.

The present invention relates to a ligand of AxI receptor tyrosine kinase used to induce the differentiation from precursor natural killer cell to mature natural killer-cell. In addition, it relates to a process for producing mature natural killer cell comprising treating hematopoietic stem cell with interleukin-7, stem cell factor and Flt3L to differentiate into precursor natural killer cell, and treating the resulting precursor natural killer cell with ligand of AxI receptor tyrosine kinase to produce mature natural killer cell.

Flt3-ligand can be used to generate large numbers of dendritic cells from hematopoietic progenitor and stem cells. Flt3-ligand can be used to augment immune responses in vivo, and expand dendritic cells ex vivo. Such dendritic cells can then be used to present tumor, viral or other antigens to naive T cells, can be useful as vaccine adjuvants. When flt3-L is used and / or administered in combination with other reactive agents, e.g. CD40 binding proteins and 4-1BBL or antibodies reactive with 4-1BB, the combination further enhances immune responses and the effectiveness of vaccine adjuvants.

The present invention provides a composition for raising an immune response against a tumor. The composition comprises at least one tumor antigen, a saponin-based adjuvant, a TLR ligand and a Flt3 ligand.

In various embodiments methods of producing a cell population enriched for CLEC9A+ dendritic cells are provided where the methods involve culturing stem cells and / or progenitor cells in a cell culture comprising culture medium, a notch ligand, stem cell factor (SCF), FLT3 ligand (FLT3L); thrombopoietin (TPO); and IL-3 and / or GMCSF.

In the present invention, CD8+ conventional dendritic cells (CD8+ cDCs) and equivalents thereof (eCD8+ cDCs) in mouse and human have been established as major source of IFN-lambda (IFN-λ) in response to double-stranded (ds) nucleic acids. The invention relates to therapeutic applications of ds nucleic acids or analogs thereof targeting CD8+ and / or eCD8+ cDCs in the prevention and / or treatment of infectious diseases, preferably viral infections, or cancer. Furthermore, the invention relates to an in vitro method for producing IFN-λ and / or generating or obtaining a population of IFN-λ producing CD8+ or eCD8+ cDCs as well as in vitro method for detecting or screening for CD8+ and / or eCD8+ cDCs. In addition, the invention relates to a Flt3-ligand or a M-CSF receptor ligand for use in increasing the level of CD8+ and / or eCD8+ cDCs in a subject suffering from an infectious disease or cancer.

The invention discloses an encoding chimeric antigen receptor nucleic acid molecule. The chimeric antigen receptor comprises an extracellular region, a transmembrane domain and an intracellular signaltransduction domain, wherein the encoded extracellular region comprises an FLT3 binding structural domain, and the FLT3 binding structural domain is an FLT3 ligand or an amino acid sequence with the90 to 99% identity as the FLT3 ligand. A flow cytometry, a degranulation analysis experiment and cytokines secreted by ELISA detection T cells prove that T cells modified by the chimeric antigen receptor have a strong killing effect of leukemia cells for expressing FLT3, especially have a specific killing effect on AML cells carrying FLT3 mutant and can effectively prevent an off-target effect. The chimeric antigen receptor FLT3L-CD8 alpha-4-1BB-CD3 zeta disclosed by the invention can be applied to treating FLT3+leukemia, especially leukemia carrying the FLT3 mutant.

Ligands for flt3 receptors capable of transducing self-renewal signals to regulate the growth, proliferation or differentiation of progenitor cells and stem cells are disclosed. The invention is directed to flt3-L as an isolated protein, the DNA encoding the flt3-L, host cells transfected with cDNAs encoding flt3-L, compositions comprising flt3-L, methods of improving gene transfer to a mammal using flt3-L, and methods of improving transplantations using flt3-L. Flt3 -L finds use in treating patients with anemia, AIDS and various cancers.

Ligands for flt3 receptors capable of transducing self-renewal signals to regulate the growth, proliferation or differentiation of progenitor cells and stem cells are disclosed. The invention is directed to Flt3-ligand as an isolated protein, the DNA encoding the Flt3-ligand, host cells transfected with cDNAs encoding Flt3-ligand, compositions comprising Flt3-ligand and methods of using Flt3-ligand in hematopoietic cell transplantation.

Flt3 ligand from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding said ligand. Methods of using said reagents and diagnostic kits are also provided.

The invention provides a serum-free medium and a method for amplifying hematopoietic stem cells. The serum-free culture medium comprises a serum-free basal culture medium, cytohormone, an umbilical cord mesenchymal stem cell conditioned culture medium and auxiliary components. The cytohormone comprises a stem cell factor, thrombopoietin and a hematopoietic growth factor Flt3 ligand. The umbilicalcord mesenchymal stem cell conditioned medium is derived from cultured human umbilical cord mesenchymal stem cells. The auxiliary components comprise vitamin C, vitamin E or a combination of vitamin Cand vitamin E.

The invention relates (i) to pyridine-pyridinone derivatives with the formula (I): where R1 is a hydrogen atom or a (C1-C4)alkyl group; R2 is a (CH2)n-B group, in which n' = 0, 1, 2, 3 or 4 and B is a (C3-C5)cycloalkyl group, a (C1-C4)alkyl group or a (C1-C4)alkoxy group; Y, Z, V and W are, independently from one another, a -CH- group, a carbon atom, a heteroatom or no atom, with the understanding that the cycle, which includes V, W, Y and Z, is a cycle including 5 or 6 members, with the understanding that the dotted lines in said cycle indicate that the resulting cycle is an aromatic cycle and with the understanding that said cycle includes 0, 1 or 2 heteroatoms; R3 and R4 are, independently from one another, identical or different groups selected among a hydrogen atom and a straight (C1-C4)alkyl group, or form a (C3-C5)cycloalkyl group together with the carbon to which the former are bonded; m is an integer equal to 1, 2, 3 or 4; R5 is a hydrogen atom or a (C1-C4)alkyl group; R6 is a (CH2)n-L group where n = 0, 1, 2 or 3, and L is a group selected among aryls with 6 carbon atoms, heteroaryls having 5 or 6 members, the saturated heterocycles including 5, 6 or 7 members or forming a heterocycle group together with the nitrogen atom to which the former are linked. The invention also relates (ii) to the preparation of said derivatives, and (iii) to the therapeutic use thereof as inhibitors of kinase activity in receptors having PDGF ligands and / or receptors with the FLT3 ligand.

Ligands for flt3 receptors capable of transducing self-renewal signals to regulate the growth, proliferation or differentiation of progenitor cells and stem cells are disclosed. The invention is directed to Flt3-ligand as an isolated protein, the DNA encoding the Flt3-ligand, host cells transfected with cDNAs encoding Flt3-ligand, compositions comprising Flt3-ligand and methods of using Flt3-ligand in hematopoietic cell transplantation.

The present invention relates to a method for producing human mast cells from human pluripotent stem cells. More particularly, the present invention provides a method for producing human mast cells from human pluripotent stem cells, comprising the steps of: (a) culturing human pluripotent stem cells under a condition suitable for promoting differentiation of the human pluripotent stem cells into hematopoietic progenitor cells expressing CD34; and (b) culturing the cells obtained in step (a) in the presence of hematopoietic factors comprising thrombopoietin (TPO) and Flt3 ligand.